This finding underscores the importance of careful consideration for pharmacological IKKβ inhibition advocated for the treatment of NAFLD and NASH [40] as this systemic approach most likely results in harmful effects of hepatocyte IKKβ inhibition counteracting beneficial effects on myeloid cells. Here, IKBKB is linked to metabolic dysfunction-associated steatohepatitis.